Intriguingly, neoantigenic vaccines can upregulate PD-1/PD-L1 expression, leading to immunosuppression that affects steps three and six of the cancer-immunity cycle, and limiting vaccine-induced tumor regression [139, 143]. This evidence concerns the gene PDCD1 and neoplasm.